The Human Papillomavirus Oncoprotein E7 Attenuates NF-κB Activation by Targeting the IκB Kinase Complex*
暂无分享,去创建一个
[1] F. Vikhanskaya,et al. Human papillomavirus type 16 E6‐enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line , 2002, International journal of cancer.
[2] R. Wu,et al. Increased p50/p50 NF-κB Activation in Human Papillomavirus Type 6- or Type 11-Induced Laryngeal Papilloma Tissue , 2002, Journal of Virology.
[3] R. Tindle. Immune evasion in human papillomavirus-associated cervical cancer , 2002, Nature Reviews Cancer.
[4] T. Maniatis,et al. NF-(cid:1) B signaling pathways in mammalian and insect innate immunity , 2001 .
[5] A. Sampath,et al. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells , 2001, Oncogene.
[6] C. Woodworth,et al. Papillomavirus Type 16 Oncogenes Downregulate Expression of Interferon-Responsive Genes and Upregulate Proliferation-Associated and NF-κB-Responsive Genes in Cervical Keratinocytes , 2001, Journal of Virology.
[7] J. Nevins,et al. The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.
[8] Chris Albanese,et al. NF-κB and cell-cycle regulation: the cyclin connection , 2001 .
[9] J. Mazzarelli,et al. Oligomerization properties of the viral oncoproteins adenovirus E1A and human papillomavirus E7 and their complexes with the retinoblastoma protein. , 2000, Biochemistry.
[10] G. Blair,et al. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins , 2000, Oncogene.
[11] P. Cohen,et al. Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3 , 2000, Molecular and Cellular Biology.
[12] W. Chien,et al. Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[13] J. de Graaf,et al. A functional NF-kappaB binding site in the human papillomavirus type 16 long control region. , 2000, Virology.
[14] Ajay Mahaputra Kumar,et al. PKN Binds and Phosphorylates Human Papillomavirus E6 Oncoprotein* , 2000, The Journal of Biological Chemistry.
[15] F. Dick,et al. Mutagenesis of the pRB Pocket Reveals that Cell Cycle Arrest Functions Are Separable from Binding to Viral Oncoproteins , 2000, Molecular and Cellular Biology.
[16] Harald zur Hausen,et al. Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis , 2000 .
[17] K. Vousden,et al. Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.
[18] A. Israël. The IKK complex: an integrator of all signals that activate NF-κB? , 2000 .
[19] T. Hofmann,et al. Mixed-Lineage Kinase 3 Delivers CD3/CD28-Derived Signals into the IκB Kinase Complex , 2000, Molecular and Cellular Biology.
[20] W. Nickel,et al. Allosteric Activation of Acid α-Glucosidase by the Human Papillomavirus E7 Protein* , 2000, The Journal of Biological Chemistry.
[21] Jong-Sup Park,et al. Inactivation of Interferon Regulatory Factor-1 Tumor Suppressor Protein by HPV E7 Oncoprotein , 2000, The Journal of Biological Chemistry.
[22] S. Caldeira,et al. Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein , 2000, Oncogene.
[23] M. Karin,et al. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.
[24] H. Hausen. Viruses in human cancers , 1991 .
[25] M. Karin,et al. JNK2 and IKKbeta are required for activating the innate response to viral infection. , 1999, Immunity.
[26] M. Henriksson,et al. Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation , 1999, Oncogene.
[27] K. Smith-McCune,et al. Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] L. Banks,et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] S. Ghosh. Regulation of inducible gene expression by the transcription factor NF-κB , 1999 .
[30] Miranda Thomas,et al. Inhibition of Bak-induced apoptosis by HPV-18 E6 , 1998, Oncogene.
[31] M. Karin,et al. JNK or IKK, AP-1 or NF-κB, which are the targets for MEK kinase 1 action? , 1998 .
[32] M. Vidal,et al. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. , 1998, Genes & development.
[33] W. Fiers,et al. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[34] D. Pim,et al. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. , 1997, The Journal of general virology.
[35] D. Wazer,et al. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. , 1996, Cancer research.
[36] M. von Knebel Doeberitz,et al. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. , 1996, Oncogene.
[37] M. Schmitz,et al. The dual effect of adenovirus type 5 E1A 13S protein on NF-kappaB activation is antagonized by E1B 19K , 1996, Molecular and cellular biology.
[38] M. Birrer,et al. The human papillomavirus type 16 E7 gene product interacts with and trans‐activates the AP1 family of transcription factors. , 1996, The EMBO journal.
[39] L. Laimins,et al. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. , 1996, Virology.
[40] E. Tartour,et al. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. , 1994, Cancer research.
[41] M. von Knebel Doeberitz,et al. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions , 1994, Journal of virology.
[42] M. Yutsudo,et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. , 1994, Virology.
[43] T. Luger,et al. Increased tumorigenicity of human keratinocytes harboring human papillomavirus type 16 is associated with resistance to endogenous tumor necrosis factor‐α‐mediated growth limitation , 1994, International journal of cancer.
[44] N. Hachiya,et al. Functional oligomerization of purified human papillomavirus types 16 and 6b E7 proteins expressed in Escherichia coli. , 1994, The Journal of general virology.
[45] M. Scheffner,et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.
[46] T. Gilmore. Role of rel family genes in normal and malignant lymphoid cell growth. , 1992, Cancer surveys.
[47] P. Baeuerle,et al. The p65 subunit is responsible for the strong transcription activating potential of NF‐kappa B. , 1991, The EMBO journal.
[48] S. Nagata,et al. pEF-BOS, a powerful mammalian expression vector. , 1990, Nucleic acids research.
[49] A. Levine,et al. Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.
[50] D. Lowy,et al. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. , 1989, The EMBO journal.
[51] K. Münger,et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.
[52] T. Crook,et al. Continued expression of HPV‐16 E7 protein is required for maintenance of the transformed phenotype of cells co‐transformed by HPV‐16 plus EJ‐ras. , 1989, The EMBO journal.